C.F.R. homeSearch C.F.R.
C.F.R.Title 42Chapter IV—Centers for Medicare & Medicaid Services, Department of Health and Human ServicesSubchapter B—Medicare ProgramPart 405—Federal Health Insurance for the Aged and DisabledSubpart B—Medical Services Coverage Decisions That Relate to Health Care Technology

42 C.F.R. § 405.201 (2026)

Scope of subpart and definitions

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1986–2025 14citing cases
At a glance

Courts have cited this section in 14 opinions since 1986, 1 of them in the last five years. The most litigated part is subsection (b) (2 cases).

(a) Scope. This subpart establishes that—

(1) CMS uses the FDA categorization of a device as a factor in making Medicare coverage decisions; and

(2) CMS may consider for Medicare coverage certain devices with an FDA-approved investigational device exemption (IDE) that have been categorized as Category B (Nonexperimental/investigational) device.

(3) CMS identifies criteria for coverage of items and services furnished in IDE studies.

(b) Definitions. As used in this subpart—

Category A (Experimental) device refers to a device for which “absolute risk” of the device type has not been established (that is, initial questions of safety and effectiveness have not been resolved) and the FDA is unsure whether the device type can be safe and effective.

Category B (Nonexperimental/investigational) device refers to a device for which the incremental risk is the primary risk in question (that is, initial questions of safety and effectiveness of that device type have been resolved), or it is known that the device type can be safe and effective because, for example, other manufacturers have obtained FDA premarket approval or clearance for that device type.

ClinicalTrials.gov refers to the National Institutes of Health's National Library of Medicine's online registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

Contractors refers to Medicare Administrative Contractors and other entities that contract with CMS to review and adjudicate claims for Medicare payment of items and services.

Investigational device exemption (IDE) refers to an FDA-approved IDE application that permits a device, which would otherwise be subject to marketing approval or clearance, to be shipped lawfully for the purpose of conducting a clinical study in accordance with 21 U.S.C. 360j(g) and 21 CFR part 812.

Routine care items and services refers to items and services that are otherwise generally available to Medicare beneficiaries (that is, a benefit category exists, it is not statutorily excluded, and there is no national noncoverage decision) that are furnished during a clinical study and that would be otherwise furnished even if the beneficiary were not enrolled in a clinical study.

[60 FR 48423, Sept. 19, 1995, as amended at 78 FR 74809, Dec. 10, 2013; 86 FR 3009, Jan. 14, 2021; 86 FR 62958, Nov. 15, 2021]
The 14 cases that cite 42 C.F.R. § 405.201 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENUnited States ex rel. Modglin v. DJO Global Inc., 48 F. Supp. 3d 1362 (C.D. Cal. 2014).
cites § 405.201 5×cited by 44 cases
Where it cites § 405.201
“16 42 C.F.R. § 405.201 (b). Class III devices that do not have PMA approval cannot be marketed and are considered “adulterated.”
The case’s holding
Nondisclosure of off-label use of a device is immaterial to Medicare reimbursement where Medicare coverage does not depend on on-label use; courts may judicially notice government websites.
Later courts cite it for
“under rule 201, the 22 court can take judicial notice of public records and government documents available from reliable sources on the internet, such as websites run by governmental 23 agencies.” · 5 citing courts
2
GREENUS ex rel. Bennett v. Medtronic, Inc., 747 F. Supp. 2d 745 (S.D. Tex. 2010).
cites § 405.201 5×cited by 32 cases
Where it cites § 405.201
“See 42 C.F.R. §§ 405.201 (b), 405.203, 405.211(b).”
The case’s holding
Liability under the False Claims Act requires a material false statement or fraudulent conduct that causes the government to pay or forfeit money.
Later courts cite it for
“includes a certification of compliance with a federal statute, regulation, or contract that is a prerequisite to obtaining the government benefit.” · 2 citing courts
3
GREENUnited States ex rel. Modglin v. DJO Global Inc., 114 F. Supp. 3d 993 (C.D. Cal. 2015).
cites § 405.201 3×cited by 25 cases
Where it cites § 405.201
“23 42 C.F.R. § 405.201 (b). Class III devices that do not have PMA-approval cannot be marketed and are considered “adulterated.”
4
GREENIn re Cardiac Devices Qui Tam Litig., 221 F.R.D. 318 (D. Conn. 2004).
cites § 405.201 2×cited by 43 cases
Where it cites § 405.201
“See 42 C.F.R. §§ 405.201 (b), 405.203, 405.211(b).”
The case’s holding
A plaintiff need not plead specific details for every instance of fraudulent conduct when an alleged scheme involves numerous transactions occurring over a long period of time.
Later courts cite it for
“where the alleged fraudulent scheme involved numerous transactions that occurred over a long period of time, courts have found it impractical to require the plaintiff to plead the specifics with respect to each and every instance of fraudulent conduct.” · 5 citing courts
5
GREENUnited States ex rel. Nowak v. Medtronic, Inc., 806 F. Supp. 2d 310 (D. Mass. 2011).
cites § 405.201 2×cited by 32 cases
Where it cites § 405.201
“Class II” — such as Medtronic’s biliary stents at issue in this case — are Category B, “nonexperimental/investigational” devices, 42 C.F.R. § 405.201 (b), which Medicare contractors “may approve .”
The case’s holding
Relators must allege specific details regarding each asserted state claim and cannot rely on generalized pleadings to satisfy the particularity requirements of Rule 9(b).
Later courts cite it for
“in order to satisfy rule 9(b), relators must allege some specificity with respect to each asserted state and cannot rely upon generalized pleadings.” · 3 citing courts
6
GREENUnited States ex rel. Witkin v. Medtronic, Inc., 189 F. Supp. 3d 259 (D. Mass. 2016).
cites § 405.201 1×cited by 9 cases
Where it cites § 405.201
“5725 ; 42 C.F.R. § 405.201 (b); see Sec. Am. Compl.”
7
GREENHarris v. Olszewski, 442 F.3d 456 (6th Cir. 2006).
cites § 405.201 1×cited by 71 cases
Where it cites § 405.201
“§ 1395y(m)(2); 42 C.F.R. § 405.201 (b). Having failed to enact a definition of “medical devices” that precludes the phrase from covering “incontinence products,” having used a phrase that has a range of meanings, including one that naturally extends to incontinence products, and…”
The case’s holding
The Medicaid freedom-of-choice provision creates an enforceable individual right under section 1983.
Later courts cite it for
“if it has, 'that is the end of the matter; for the court, as well as the agency, must give effect to the unambiguously expressed intent of congress.” · 3 citing courts
8
GREENAlmy v. Sebelius, 749 F. Supp. 2d 315 (D. Md. 2010).
cites § 405.201 1×cited by 7 cases
Where it cites § 405.201
“See 42 C.F.R. § 405.201 (a)(1) (“CMS uses the FDA categorization of a device as a factor in making Medicare coverage determinations.”
9
GREENAm. Hosp. Ass'n v. Bowen, 640 F. Supp. 453 (D.D.C. 1986).
cites § 405.201 1×cited by 10 cases
Where it cites § 405.201
“1079 also refers to 42 C.F.R. § 405.201 (c), which governs who may act as a beneficiary’s representative in an appeal from a non-coverage determination.”
Later courts cite it for
“original obligations imposed by hhs on pros and hospitals” · 1 citing court
10
GREENYale-New Haven Hosp., Inc. v. Thompson, 162 F. Supp. 2d 54 (D. Conn. 2001).
cites § 405.201 1×cited by 4 cases
Where it cites § 405.201
“42 C.F.R. §§ 405.201 (b); 405.203. The intermediaries may approve coverage for any non-experimental/investi-gational IDE device in Category B if all other coverage requirements have been met.”
11
GREENYale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).
cites § 405.201 2×subsections: (b)cited by 3 cases
Where it cites § 405.201
“3 42 C.F.R. §§ 405.201 (b), 405.211(b). The FDA classified all other devices in Category A (experimental/investigational), which continued to be excluded from Medicare coverage.”
Later courts cite it for
“generally speaking, after-the-fact rationalization for agency action is disfavored.” · 4 citing courts
12
GREENInt'l Rehabilitative Sciences, Inc. v. Sebelius, 737 F. Supp. 2d 1281 (W.D. Wash. 2010).
cites § 405.201 1×cited by 2 cases
Where it cites § 405.201
“” 42 C.F.R. § 405.201 (a)(1). The Secretary has stated that “CMS adopts FDA determinations of safety and effectiveness”, but that “[ajlthough an FDA-regulated product must receive FDA approval or clearance for at least one indication to be eligible for Medicare coverage, .”
Later courts cite it for
“more based on substantial evidence than the medicare appeals council denials at issue here.” · 1 citing court
13
NO FLAGLisenby v. Olympus Corp. of the Americas, No. 5:24-cv-01803 (E.D. Pa. Feb. 25, 2025).
cites § 405.201 3×cited by 0 casesunknown
Where it cites § 405.201
“, 42 C.F.R. § 405.201 (a)(1).”3 Id. Plaintiff asserts that “Defendants have also sold devices to the Veterans Administration while representing that those devices were FDA-approved, and where FDA approval was a material condition of purchase.”
14
GREENYale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).
cites § 405.201 1×subsections: (b)cited by 0 cases
Where it cites § 405.201
“" 42 C.F.R. 405.201(b) 4 The government intervened in that case in 2002; the opinion in an appeal of a decision in that case, see In re Cardiac Devices Qui Tam Litig.”
The case’s holding
An agency action is arbitrary and capricious if the agency fails to provide a reasoned explanation for a change in policy, as after-the-fact rationalization is generally disfavored.

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198620052025

One bar per year. Tallest: 3 cases in 2006. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
2d Cir.2C.D. Cal.2D. Conn.2D. Mass.26th Cir.1D.D.C.1D. Md.1E.D. Pa.1

The 8 courts with the most citing cases, of 10 courts in all.

By subsection
(b)2 cases
Yale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).“3 42 C.F.R. §§ 405.201 (b), 405.211(b). The FDA classified all other devices in Category A (experimental/investigational), which continued to be excluded from Medicare coverage.”
Yale-New Haven Hosp. v. Leavitt, 470 F.3d 71 (2d Cir. 2006).“" 42 C.F.R. 405.201(b) 4 The government intervened in that case in 2002; the opinion in an appeal of a decision in that case, see In re Cardiac Devices Qui Tam Litig.”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com